【摘要】 目的了解北京市乙肝感染不同结局者治疗现状及年均总费用,为进一步完善北京市乙肝防治策略提供卫生经济学证据。方法以人群为基础的多阶段抽样和医院为基础的乙肝病例随机抽样相结合的方法,收集乙肝病毒(HBV)感染不同结局相关病例1 587例,调查其2009-07-01—2010-06-30因乙肝相关费用。结果共收集急性乙型肝炎89例、乙肝病毒携带者274例、慢性乙型肝炎973例、肝硬化139例、肝癌112例。人均总费用分别为:急性乙型肝炎22 941.68元、乙肝病毒携带者1 007.90元、慢性乙型肝炎11 777.28元、肝硬化54 473.94元和肝癌128 309.35元。肝硬化及肝癌患者年均总费用为当年人均可支配收入的2.04倍和4.80倍。1/3的慢性乙型肝炎患者从未接受过抗病毒治疗。结论北京市乙肝相关疾病,尤其是肝硬化和肝癌给患者造成较大经济负担;慢性乙型肝炎患者的抗病毒治疗率有待进一步提高。更多还原

【Abstract】 Objective To understand the economic burden for the patients with hepatitis B virus infection in Beijing and to provide health economic evidence for hepatitis B( HB) control. Methods A community-based household survey combined with a hospital-based sampling investigation was used to collect the annual cost of the patients with acute HB,HBs Ag carrier,chronic HB,cirrhosis and hepatocellular carcinoma( HCC). Results A total of 1 587 HBV infection-related cases were enrolled,including 89 acute HB,274 HB carrier,973 chronic HB,139 cirrhosis,and 112 HCC. The average annual total cost in 2009 was as follows: acute HB, $ 22 941. 68; HBV carrier,$ 1 007. 90; chronic HB, $ 11 777. 28; cirrhosis, $ 54 473. 94 and HCC, $ 128 309. 35. The average annual total cost for cirrhosis and HCC patients was 2. 03 and 4. 80 times higher than annual per capita income,respectively.One-third of patients with chronic HB have never been treated with antivirals. Conclusions HBV related infection has brought great economic burden to the patients,especially cirrhosis and HCC. Anti-viral treatment rate in chronic HB patients should be improved in the future.更多还原